Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

Inclusion Criteria

• •1. Kidney transplant recipient
• •2. Age 2-17 years, inclusive, at the time of first study dose
• •3. Estimated GFR (eGFR) ≥30 ml/min/1.73m2, with stable allograft function as indicated by \<20% change in serum creatinine in the previous 30 days
• •4. Stable immunosuppressive regimen, as indicated by \<10% change in dosage (in mg/kg) in these medications, within the 14 days prior to enrollment
• •5. Systolic BP \>90th percentile for age, gender, and height, necessitating initiation or addition of an antihypertensive medication
• •6. For females of child-bearing potential, a negative serum pregnancy test prior to initial dosing and agreement to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy testing through the remainder of the study (30 days after last administration of investigational agents).